- Home
- Applications
- europe
- human proteomics
Show results for
Refine by
Human Proteomics Product Applications Available In Europe
5 applications found
Many key protein functions require the protein to undergo a post-translational modification (PTM), examples ranging from phosphorylations and glycosylations to histone modifications and ubiquitinations. HuProt human proteome microarrays can be used for profiling the targets of enzymes producing PTMs and have been used in studies of phosphorylation, glycosylation, sumoylation, ...
ByCambridge Protein Arrays Ltd. (CPAP) based in Cambridge, UNITED KINGDOM
The concept behind protein arrays is the immobilisation of sets of proteins, up to very large numbers, on solid supports, to perform miniaturised, multiplexed binding assays with a variety of potential ligands or interactants (see powerpoint presentation on right). HuProt v4 human proteome arrays as used at CPA comprise full length human proteins, many of which will retain their native conformation. ...
ByCambridge Protein Arrays Ltd. (CPAP) based in Cambridge, UNITED KINGDOM
Profiling of nucleic acid binding on HuProt human proteome microarrays can reveal interactions with the largest collection of individual human proteins available on a single slide. ...
ByCambridge Protein Arrays Ltd. (CPAP) based in Cambridge, UNITED KINGDOM
Determine the interactome of your favourite protein. HuProt arrays provide a primary platform for screening proteins for binary interactions with the world's largest collection of human proteins immobilised on a single microarray. Over 20,000 potential interactions are assessed in a single experiment. Array screening facilitates detection of interactors with low abundance in cellular systems. Combined with other data, the array output can confirm known interactors and discover new ones, illuminating the protein ...
ByCambridge Protein Arrays Ltd. (CPAP) based in Cambridge, UNITED KINGDOM
Comprehensive antibody reactivity profiling: validate specificity, identify cross-reactions. The issue of antibody cross-reactivity is one that has often been often overlooked or sidelined in the past, with typical antibody QC involving evidence of binding to the intended target, while neglecting potential cross-reactivity. In recent years, however, many examples have come to light where poor validation of antibodies has led to misleading or erroneous conclusions for assays in which they are used as reagents, due ...
ByCambridge Protein Arrays Ltd. (CPAP) based in Cambridge, UNITED KINGDOM